Linde, LouiseØrnbjerg, Lykke MidtbøllGeorgiadis, StylianosRasmussen, Simon H.Lindström, UlfAskling, JohanMichelsen, BrigitteDi Giuseppe, DanielaWallman, Johan KGudbjornsson, BjornLove, Thorvardur JonNordström, DanYli-Kerttula, TimoNekvindova, LucieVencovský, JiříIannone, FlorenzoCauli, AlbertoLoft, Anne GitteGlintborg, BenteLaas, KarinRotar, ZigaTomšič, MatijaMacfarlane, GaryMöller, BurkhardVan de Sande, Marleen G.H.Codreanu, CatalinNissen, Michael JBirlik, MerihErten, SukranSantos, Maria JVieira-Sousa, ElsaHetland, Merete LundØstergaard, Mikkel2024-03-072024-03-072024-03-01Linde, L, Ørnbjerg, L M, Georgiadis, S, Rasmussen, S H, Lindström, U, Askling, J, Michelsen, B, Di Giuseppe, D, Wallman, J K, Gudbjornsson, B, Love, T J, Nordström, D, Yli-Kerttula, T, Nekvindova, L, Vencovský, J, Iannone, F, Cauli, A, Loft, A G, Glintborg, B, Laas, K, Rotar, Z, Tomšič, M, Macfarlane, G, Möller, B, Van de Sande, M G H, Codreanu, C, Nissen, M J, Birlik, M, Erten, S, Santos, M J, Vieira-Sousa, E, Hetland, M L & Østergaard, M 2024, 'Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor : results from 13 European registries', Rheumatology, vol. 63, no. 3, pp. 751–764. https://doi.org/10.1093/rheumatology/kead2841462-0324ORCID: /0000-0003-2322-3314/work/138946064https://hdl.handle.net/2164/22933The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript.161258035engpsoriatic arthritisfirst TNF-inhibitorpredictorsDAPSA28drug retentionreal-world evidenceR MedicineSupplementary DataRJournal article10.1093/rheumatology/kead284633